This research article from the European Journal of Neurology presents the results of the ADVANCE-CIDP IVIG trial, which investigated the effectiveness and safety of intravenous immunoglobulin 10% therapy (GAMMAGARD LIQUID/Kiovig) for treating relapses in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study found that IVIG 10% was effective in treating CIDP relapses and improving functional abilities, with a high responder rate and a favorable safety profile in patients who had relapsed during a previous trial of subcutaneous immunoglobulin or placebo. These findings support the use of IVIG 10% as a rescue therapy for CIDP relapse, and contributed to its recent approval in the United States for this purpose.